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MenaINV dysregulates cortactin 
phosphorylation to promote 
invadopodium maturation
Maxwell D. Weidmann1, Chinmay R. Surve1,2, Robert J. Eddy1, Xiaoming Chen1, 
Frank B. Gertler4, Ved P. Sharma1,3 & John S. Condeelis1,2,3
Invadopodia, actin-based protrusions of invasive carcinoma cells that focally activate extracellular 
matrix-degrading proteases, are essential for the migration and intravasation of tumor cells during 
dissemination from the primary tumor. We have previously shown that cortactin phosphorylation 
at tyrosine residues, in particular tyrosine 421, promotes actin polymerization at newly-forming 
invadopodia, promoting their maturation to matrix-degrading structures. However, the mechanism by 
which cells regulate the cortactin tyrosine phosphorylation-dephosphorylation cycle at invadopodia 
is unknown. Mena, an actin barbed-end capping protein antagonist, is expressed as various splice-
isoforms. The MenaINV isoform is upregulated in migratory and invasive sub-populations of breast 
carcinoma cells, and is involved in tumor cell intravasation. Here we show that forced MenaINV 
expression increases invadopodium maturation to a far greater extent than equivalent expression of 
other Mena isoforms. MenaINV is recruited to invadopodium precursors just after their initial assembly 
at the plasma membrane, and promotes the phosphorylation of cortactin tyrosine 421 at invadopodia. 
In addition, we show that cortactin phosphorylation at tyrosine 421 is suppressed by the phosphatase 
PTP1B, and that PTP1B localization to the invadopodium is reduced by MenaINV expression. We 
conclude that MenaINV promotes invadopodium maturation by inhibiting normal dephosphorylation of 
cortactin at tyrosine 421 by the phosphatase PTP1B.
It is estimated that 90% of deaths from solid tumors are not caused by the primary tumor, but the further dissem-
ination and growth of secondary and tertiary tumors at distal sites, known as metastases1,2. In order to escape the 
primary tumor, breast carcinoma cells must first penetrate their native basement membrane, the dense extracel-
lular matrix (ECM) of the tumor stroma, and the endothelium basement membrane before entering the blood-
stream3,4. There is increasing evidence that both the basement membrane and dense networks of cross-linked 
type-1 collagen in the tumor stroma present significant barriers to tumor cell invasion5–7. Penetrating these barri-
ers requires invading tumor cells to produce actin-based proteolytic protrusions termed invadopodia7–10.
The level of invadopodium formation and matrix degradation has been shown to directly correlate with inva-
sion both in vivo and in vitro10–13. Invadopodia have been identified in mammary tumors using in vivo imaging9,14, 
and inhibition of invadopodium formation reduces invasion, intravasation and metastasis of breast carcinoma 
cells9,10,15. Recent work has shown that macrophage-induced invadopodium formation is necessary for in vitro 
trans-endothelial migration of breast carcinoma cells derived from patients and breast carcinoma cells entering 
the bloodstream in vivo15.
Invadopodium formation and maturation into a proteolytic structure occurs in several stages after stimulation 
by a growth factor, such as EGF, integrin signaling16,17 and/or macrophage contact15. Within seconds of stimula-
tion, the binding of a complex of proteins to F-actin puncta, including cortactin, cofilin, N-WASP, Nck1, WIP and 
Arp2/3, forms the invadopodium “precursor” core13,18,19. Approximately 20 s after the formation of this core com-
plex, Tks5 recruitment and binding to phospholipid PI(3,4)P2 begins the process of invadopodium stabilization 
at the plasma membrane20. Further stabilization, protrusion and maturation of the precursor requires cortactin 
phosphorylation of at least tyrosine 421 by the kinase Arg17,21,22.
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Figure 1. MenaINV localizes to invadopodia in breast tumor cells. (A) Mena isoforms localize to 
invadopodium precursors. Representative images of MTLn3 cells expressing eGFP-Mena, eGFP-MenaINV or 
eGFP-Mena11a showing co-localization of Mena isoforms with invadopodium markers. The cells were plated 
on fluorescently-labeled gelatin in complete media, fixed and immunostained for Tks5 and cortactin. Yellow 
arrows indicate regions of co-localization in all 3 channels depicted (n = three independent experiments). 
(B) Endogenous Mena localizes to the invadopodium. Representative images of MTLn3 cells showing co-
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Phosphorylation of cortactin at tyrosine 421 recruits the sodium-hydrogen exchanger NHE1, which increases 
the local intracellular pH and triggers F-actin severing by releasing active cofilin from cortactin23,24. Cortactin 
phosphorylation also recruits Nck1/N-WASP to stimulate Arp2/3 activity, which acts synergistically with cofilin 
severing of actin filaments to promote actin polymerization and invadopodium protrusion17,22,25. The dephos-
phorylation of cortactin reverses this process thereby inhibiting cofilin activity and actin polymerization17,25. 
However, the phosphatases responsible for cortactin dephosphorylation at tyrosine 421 in invadopodia remain 
unidentified.
Gene expression profiling of invasive and migrating subpopulations of breast carcinoma cells identified an 
“invasion signature” containing the Arp2/3, cofilin and Mena regulatory pathways that are essential for cell 
migration and invadopodium formation26–29. Mena is a member of the Enabled/vasodilator-stimulated phos-
phoprotein (Ena/VASP) family30, known to regulate actin cytoskeletal geometry and promote the elongation of 
actin filaments during membrane protrusion by antagonizing barbed end capping activity31,32. Mena localizes 
to the leading edge, focal adhesions and the tips of filopodia via its Ena/VASP Homolog 1 (EVH1) domain30,33,34 
and to PI(3,4)P2-rich regions of membrane found in invadopodia20,35. The EVH1 domain of Mena binds to 
a consensus motif (FP4) on specific targeting proteins, such as Lamellipodin, which localize Mena to each of 
these locations20,33,35–37. Mena also binds directly to the cytoplasmic tail of the α 5 integrin subunit and promotes 
bi-directional signaling through α 5β 1 integrin, a major receptor for fibronectin38,39.
Mena contains several additional exons that may be expressed via alternative splicing to produce isoforms 
with distinct expression patterns in invasive and non-invasive populations of tumor cells30,40–42. In particular, 
the expression of the invasion-associated Mena isoform, termed MenaINV, is upregulated in the invasive and 
migratory tumor cells relative to the non-migratory primary tumor cells26–29,42. Expression of the MenaINV iso-
form, identified by an alternatively-included exon that inserts a 19 amino-acid sequence just downstream of the 
EVH1 domain, is associated with tumor metastasis and progression in mouse models of breast carcinoma43,44. 
Expression of MenaINV in breast carcinoma cells increases invadopodium lifetime and degradative activity45.
Quantitative immunofluorescence assays of the expression of invasive Mena isoforms relative to total Mena 
expression (MenaCalc) have been developed to predict metastatic risk in patients with breast cancer46,47. Mena is 
expressed in tumor cells within sites of macrophage-contact-dependent tumor cell intravasation, termed Tumor 
Microenvironment of Metastasis (TMEM). The density of TMEM sites in patient tumor samples is an inde-
pendent predictor of metastasis that positively correlates with MenaINV expression44,48–50. Furthermore, increased 
MenaINV protein expression, detected using a MenaINV-specific antibody is associated with increased recurrence 
and decreased survival in breast cancer patients39. In contrast, expression of Mena with the 11a exon is reduced in 
the invasive and disseminating subpopulation of breast carcinoma cells40. This is interesting because expression 
of Mena11a is associated with suppression of invasion and dissemination48,51.
Over-expression of MenaINV produces tumor cells that are less cohesive and demonstrate increased inva-
sion, intravasation and lung metastasis in mouse models of breast cancer44,45,51. MenaINV also drives assembly of 
ECM networks with increased abundance of linear collagen fibrils radiating from the tumor periphery39. While 
over-expression of Mena lacking the INV exon also increases invasion and metastasis, the effects of MenaINV 
expression are significantly more potent45. Despite the close relationship between MenaINV expression and tumor 
invasiveness, the mechanism underlying MenaINV–dependent enhancement of invadopodium stability and func-
tion has not been explored.
Recent investigation into how MenaINV contributes to tumor cell invasion and dissemination has focused 
on the ability of MenaINV to sensitize invading breast cancer cells to chemotactic or haptotactic signals such as 
EGF or fibronectin present in the ECM39,43,45,51. Hughes et al.43 showed that Mena recruits the tyrosine phos-
phatase PTP1B to the EGF receptor (EGFR), but the MenaINV isoform has the unique effect of inhibiting PTP1B 
recruitment to the EGFR43. MenaINV also binds to α 5 integrin more robustly than Mena39. These findings reveal 
that inclusion of the INV sequence influences interactions of Mena with specific effector molecules. The ability 
of MenaINV to regulate PTP1B at the EGFR opens the possibility that MenaINV may promote invasion through 
affecting PTP1B in a variety of other contexts in which the phosphatase acts as a tumor suppressor52. For exam-
ple, PTP1B has been shown to bind and dephosphorylate cortactin at tyrosine 421 in human cells53,54, though 
the effect of PTP1B on invadopodium maturation has not been explored. Phosphorylation of cortactin at tyros-
ine 421 has been shown to occur at both invadopodia and the leading edge55, and is essential for both actin 
polymerization17 and ECM degradation at invadopodia56,57. While MenaINV is known to increase EGF-elicited 
localization of Mena, using a pan-Mena primary antibody that recognized all Mena isoforms, or Mena11a, 
using a Mena11a-specific antibody (Supplementary Fig. S2), with invadopodium markers. The cells were plated 
on unlabeled gelatin in complete media, fixed and stained for cortactin, Tks5, all Mena isoforms (Pan-Mena) 
and Mena11a (n = three independent experiments). (C) MenaINV localizes at the invadopodium in tumor cells 
collected from mammary tumors by fine needle aspiration. Representative images of MTLn3 cells isolated from a 
mouse xenograft tumor three weeks after transplantation in vivo (described in the Methods section). The isolated 
cells were plated on unlabeled gelatin in complete media, fixed and immunostained for MenaINV, cortactin and 
Tks5 (n = three independent experiments). (D) The percentage of invadopodium precursors, defined as cortactin- 
and Tks5-rich puncta, co-localizing with eGFP-tagged Mena, MenaINV, Mena11a or endogenous Mena (Pan-Mena 
stain) in MTLn3 cells as depicted in (A,B). (E) The percentage of mature invadopodia co-localizing with eGFP-
tagged Mena, MenaINV, Mena11a or endogenous Mena in MTLn3 cells as depicted in A-B. (n > 50 cells; three 
independent experiments). There were no statistical differences between group means as determined by one-way 
analysis of variance (ANOVA) and Tukey’s multiple comparisons test. ns = non-significant.
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phosphorylation of cortactin at tyrosine 42143, whether this increase in cortactin tyrosine 421 phosphorylation 
occurs within specific subcellular compartments, and how this contributes to tumor cell phenotype, have not 
been determined.
In this study, we investigate the specific effects of the MenaINV isoform on invadopodium biology, characterize 
the localization and arrival dynamics of MenaINV at developing invadopodia, and investigate how MenaINV may 
promote cell invasion through a direct effect on invadopodium maturation. Furthermore, we explore for the 
first time the role of PTP1B in regulating invadopodium maturation via its effect on cortactin phosphorylation 
at invadopodia, and address the possibility that MenaINV interferes with this function of PTP1B at invadopodia.
Results
Mena isoforms localize to invadopodia in breast carcinoma cells. Previous work has shown that 
Mena localizes to invadopodia in mammary carcinoma cells45. However, the differences in localization of different 
Mena isoforms (MenaINV and Mena11a) to invadopodia have not been assessed. Using both rat MTLn3 and human 
MDA-MB-231 breast carcinoma cell lines stably expressing eGFP-Mena, eGFP-MenaINV and eGFP-Mena11a, we 
found that all of these Mena isoforms co-localize with cortactin and Tks5 at invadopodium precursors (Fig. 1A; 
Figure 2. Mena isoforms expressed in invasive human and rat breast carcinoma cell lines have different 
effects on invadopodium maturation in vitro. (A) MenaINV expression promotes invadopodium maturation 
in MDA-MB-231 human breast carcinoma cell lines. Representative images of MDA-MB-231 cells expressing 
eGFP, eGFP-Mena, eGFP-MenaINV, or eGFP-Mena11a plated on Alexa Fluor 405 labeled gelatin in complete 
media and immunostained for Tks5 and cortactin (n = three independent experiments). (B) MenaINV 
expression promotes invadopodium maturation in MDA-MB-231 cells. Quantification of mature invadopodia 
in cells expressing the Mena isoforms listed in (A). Mature invadopodia were scored as the co-localization 
of Tks5- and cortactin-rich puncta with a degradation hole in the Alexa Fluor 405-labeled gelatin. (n > 90 
cells/condition; n > 30 fields/condition; three independent experiments). (C) MenaINV expression promotes 
invadopodium maturation in MTLn3 rat breast carcinoma cells. Representative images of MTLn3 cells 
expressing eGFP, eGFP-Mena, eGFP-MenaINV, and eGFP-Mena11a as in (A). (D) MenaINV expression promotes 
invadopodium maturation in MTLn3 cells. Quantification of mature invadopodia as scored in B (n > 90 cells/
condition; n > 30 fields/condition, three independent experiments). Error bars indicate ± SEM. Data was 
analyzed for statistical significance by unpaired t-test with Welch’s correction for unequal variance. *p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001.
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Figure 3. Reduction of MenaINV expression limits invadopodium maturation. (A) MenaINV knock-down 
(KD) in MDA-MB-231 cells. Western blot of lysates from MDA-MB-231 cells treated with siRNA targeting 
the INV exon of Mena or control siRNA for 72 hours, and stained with an antibody specific to MenaINV. VASP 
staining was used to control for off-target effects, and β -actin was used as a loading control. (B) MenaINV KD 
reduces invadopodium maturation in MDA-MB-231 cells. Representative images of MDA-MB-231 cells from 
A) plated on Alexa Fluor 405 labeled gelatin in complete media, and immuno-stained for invadopodium 
markers. (C) Quantification of mature invadopodia in cells treated as in B). (n > 80 cells/condition; n > 30 
fields/condition; three independent experiments). (D) MenaINV KD in eGFP-MenaINV expressing MTLn3 cells. 
Western blot of lysates from MTLn3 cells overexpressing eGFP-MenaINV, transfected with siRNA specifically 
targeting either the INV exon of Mena or control siRNA, and stained for all Mena isoforms (Pan-Mena) and 
MenaINV. VASP staining was used to control for off-target effects, and β -actin was used as a loading control. 
(E) Representative images of MLTn3 cells from (D) or expressing eGFP alone, plated on Alexa Fluor 405 
labeled gelatin in complete media, and immuno-stained for invadopodium markers. (F) Quantification of 
mature invadopodia in cells treated as in E). (n > 90 cells/condition; n > 40 fields/condition; three independent 
experiments). (G) Mena11a KD in MTLn3 cells. Western blot of lysates from MTLn3 cells overexpressing 
eGFP-Mena11a, transfected with siRNA specifically targeting the 11a exon of Mena or control siRNA, and 
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Supplementary Fig. S1). These eGFP-tagged Mena, MenaINV and Mena11a isoforms localize to approximately 40% of 
invadopodium precursors, with no significant difference in localization between the two isoforms (p = 0.8695, Fig. 1D).
We investigated whether endogenous Mena localization matched that seen in cells overexpressing 
eGFP-tagged Mena isoforms by staining parental MTLn3 cells with antibodies recognizing all Mena isoforms 
(Pan-Mena Ab) (Fig. 1B) and found that endogenous Mena localized to a similar proportion of invadopodium 
precursors (Fig. 1D). When we stained MTLn3 cells with a newly developed antibody specific to Mena11a 
(Supplementary Fig. S2E), we found that Mena11a localization to invadopodium precursors was similar to that 
of endogenous Mena (Fig. 1B). Since MTLn3 cells do not express detectible levels of MenaINV protein in cul-
ture44,58 but do so when growing in vivo40, we collected and cultured fine needle aspiration (FNA) samples from 
mouse MTLn3 xenograft tumors which are known to spontaneously express MenaINV in the tumor microenvi-
ronment40,48. These FNA-collected cells were stained with an antibody specific to MenaINV59. MenaINV staining was 
detectible in a subset of the FNA cells (5–10%), where we found that MenaINV localizes to invadopodia, as judged 
by overlap with cortactin and Tks5 immunofluorescence (Fig. 1C).
MenaINV, but not Mena11a, promotes invadopodium maturation in breast carcinoma cells. It 
has previously been shown that Mena and MenaINV expression increases extracellular matrix (ECM) degradation 
in rat breast carcinoma cells45. Since MenaINV expression has been shown to drive tumor cell invasion, while 
Mena11a expression is associated with reduced invasion44,45,51, we assessed the effect of Mena, MenaINV and 
Mena11a specifically on invadopodium maturation. We measured the number of mature invadopodia, as deter-
mined by the co-localization of invadopodia with holes in a fluorescently labeled gelatin matrix, in MDA-MB-231 
and MTLn3 cells. We overexpressed eGFP-Mena, eGFP-MenaINV and eGFP-Mena11a in MDA-MB-23143 and 
MTLn344 cells at approximately 4-fold the level of endogenous Mena expression to simulate the level of spon-
taneous MenaINV expression seen previously in the invasive subpopulations of breast carcinoma cells in vivo in 
two different mouse mammary tumors40. eGFP-MenaINV expression increased the number of mature invado-
podia per cell by approximately 8-fold in MDA-MB-231 cells and 3–4-fold in MTLn3 cells (Fig. 2). Expression 
of eGFP-Mena did not increase mature invadopodium number in MTLn3 cells (Fig. 2D), but eGFP-Mena did 
produce a significant increase in MDA-MB-231 cells (Fig. 2B). However the increase in mature invadopodium 
number produced by eGFP-Mena expression in MDA-MB-231 cells was significantly less than the increase pro-
duced by eGFP-MenaINV (Fig. 2B). In contrast, Mena11a expression did not produce an increase in the number of 
mature invadopodia per cell in either cell line (Fig. 2).
Since MDA-MB-231 cells express low but detectible levels of endogenous MenaINV in vitro (Fig. 3A)60, we used 
siRNA depletion of this endogenous MenaINV to determine if it is necessary for normal invadopodium maturation 
in these cells. We used a siRNA specific to the INV exon of Mena to deplete this endogenous MenaINV by more 
than 70% in MDA-MB-231 cells (Fig. 3A), and found that this decreased the level of mature invadopodia per 
cell by more than 50% (Fig. 3B,C). Since MTLn3 cells do not express endogenous MenaINV (Fig. 3D)44, we trans-
fected MTLn3 cells with eGFP-MenaINV and found that the increase in mature invadopodia caused by MenaINV 
overexpression was reversed when we depleted the level of exogenous MenaINV expression by more than 80% 
using siRNA specific to the INV exon (Fig. 3D–F). In contrast, depletion of Mena11a expression by more than 
80% using siRNA specifically targeting the 11a exon in MTLn3 cells overexpressing Mena11a did not have any 
effect on the number of mature invadopodia per cell (Fig. 3G–I). These results indicate that MenaINV specifically 
promotes invadopodium maturation while Mena11a has no effect.
MenaINV localizes to invadopodium precursors prior to their stabilization and accumulates at 
mature invadopodia. Having shown that expression of MenaINV, but not Mena11a, increases invadopo-
dium maturation, we next asked whether there were significant differences in the localization of these Mena iso-
forms to mature invadopodia. In MTLn3 cells stably expressing eGFP-tagged Mena, MenaINV or Mena11a, each of 
these Mena isoforms localized to approximately 80% of mature invadopodia (Fig. 1E). There were no significant 
differences between eGFP-Mena, eGFP-MenaINV, eGFP-Mena11a or staining for endogenous Mena (Pan-Mena 
Ab) in percent localization to mature invadopodia (Fig. 1E). Endogenous Mena, eGFP-Mena, eGFP-MenaINV 
and eGFP-Mena11a all localized to a significantly higher proportion of mature invadopodia than invadopodium 
precursors (Supplementary Fig. S2). Therefore, while each Mena isoform is able to localize to invadopodium 
precursors before ECM degradation begins, their localization is substantially enriched in mature invadopodia 
(Fig. 1D,E; Supplementary Fig. S2). Thus, although all Mena isoforms localize similarly to mature invadopodia, 
MenaINV and Mena11a produce different effects on the maturation process.
To examine the role of MenaINV in the stages of invadopodium precursor assembly and invadopodium matu-
ration in more detail, we next measured the arrival kinetics of Mena, MenaINV and Mena11a relative to the arrival 
of established markers of the invadopodium at various stages of maturation20. Using time-lapse imaging of live 
MLTn3 cells expressing TagRFP-cortactin and eGFP-Mena, eGFP-Mena11a or eGFP-MenaINV, we found that 
stained for all Mena isoforms (Pan-Mena) and Mena11a specifically. VASP staining was used to control for off-
target effects and β -actin was used as a loading control. (H) Representative images of MTLn3 cells in  
(G) or expressing eGFP alone, plated on Alexa Fluor 405 labeled gelatin in complete media, immuno-stained 
for invadopodium markers as in (B). (I) Quantification of mature invadopodia per cell (Tks5- and cortactin-
rich puncta co-localizing with degradation holes) of cells shown in H) (n > 90 cells/condition; n > 40 fields/
condition; three independent experiments). Error bars indicate SEM. Data was analyzed for statistical 
significance by unpaired t-test with Welch’s correction for unequal variance. *p < 0.05; ****p < 0.0001;  
ns = non-significant.
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Figure 4. MenaINV arrives at invadopodium precursors after core complex assembly, but before 
invadopodium stabilization at the plasma membrane. Time-lapse montage of TagRFP-Cortactin and  
(A) eGFP-MenaINV or (B) eGFP-Mena11a in MTLn3 cells starved for 3 h and stimulated with 5 nM EGF 
during imaging. (C) Quantification of Mena, MenaINV and Mena11a arrival delays with respect to cortactin. 
For comparison, the arrival delay of eGFP-Tks5 is also shown. Red lines indicate mean with 95% confidence 
interval. n = 21 invadopodia (Mena), 20 invadopodia (MenaINV), 22 invadopodia (Mena11a) and 11 
invadopodia (Tks5). **p < 0.01; ***p < 0.001; ****p < 0.0001.
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Mena and MenaINV co-localized with cortactin at newly-forming invadopodium precursors an average of 21 and 
18 seconds after cortactin arrival, respectively, while Mena11a arrived slightly later, approximately 32 seconds 
after cortactin (Fig. 4C). This arrival delay relative to cortactin indicates that MenaINV is recruited to the invado-
podium precursor at the same time as Tks5 (Fig. 4C)20. Thus, MenaINV arrives at the invadopodium precursor 
during a period prior to invadopodium maturation that is associated with Tks5-dependent stabilization of the 
precursor at the plasma membrane20. The arrival of MenaINV during this period of invadopodium stabilization 
and actin polymerization16 supports its role in directly promoting invadopodium maturation.
MenaINV expression increases cortactin phosphorylation at invadopodia. Having established 
both the presence of MenaINV at invadopodium precursors, and an increase in invadopodium maturation in cells 
expressing MenaINV, we began to investigate how MenaINV specifically affects invadopodium maturation. The 
tyrosine phosphorylation of cortactin by Arg kinase in response to EGFR and β 1-integrin activation have been 
shown to be key signaling steps in the transition of the invadopodium from the late precursor stage to a mature 
structure capable of degradation17,21,22,61. We therefore determined whether MenaINV was influencing the cortac-
tin phosphorylation state within invadopodia differently from that occurring with Mena11a, thereby promoting 
invadopodium stability and maturation.
To determine whether MenaINV influenced cortactin phosphorylation at invadopodia we assessed the level of 
tyrosine 421 cortactin phosphorylation in both human and rat breast carcinoma cells that were serum starved to 
reduce background levels of cortactin phosphorylation. Interestingly, we found that in MDA-MB-231 cells that 
were serum-starved MenaINV expression produced a significant increase in cortactin phosphorylation at tyrosine 
421 within invadopodia relative to the eGFP control. Mena11a expression, which did not promote invadopodium 
maturation, produced no significant effect on cortactin phosphorylation, as expected (Fig. 5). Expression of Mena 
without either the INV or 11a exons also produced an increase in cortactin phosphorylation at tyrosine 421 
within invadopodia, but this increase was significantly less than that produced by MenaINV expression (Fig. 5). 
Thus expression of MenaINV and, to a lesser extent, Mena, but not Mena11a increases cortactin phosphorylation 
at tyrosine 421 independently of exogenous soluble growth factors, such as EGF or HGF. Given the known reg-
ulation of invadopodium maturation by cortactin phosphorylation, the ability of MenaINV to increase cortactin 
phosphorylation at invadopodia may, at least in part, underlie MenaINV-driven increases in invadopodium mat-
uration and matrix degradation16,23,24,62.
To determine if the increase in mature invadopodia produced by MenaINV expression is dependent on the 
increase in cortactin tyrosine 421 phosphorylation, we used a non-phosphorylatable Y > F mutant of cortac-
tin. If the increase in invadopodium maturation caused by MenaINV expression is dependent on cortactin 
phosphorylation, then cells expressing the phosphorylation-deficient mutant of cortactin should not produce 
additional mature invadopodia when MenaINV is overexpressed. MDA-MB-231 cells stably expressing wild-type 
murine cortactin (cortactin-WT) or a cortactin mutant incapable of being phosphorylated at tyrosine 421 
(cortactin-Y421F), were each depleted of endogenous human cortactin (Supplementary Fig. S3) and transfected 
with eGFP or eGFP-MenaINV. Quantification of the number of mature invadopodia that formed after plating the 
cells on a thin fluorescent ECM indicated that MenaINV expression increased the number of mature invadopodia 
in cells expressing cortactin-WT by 3–4-fold, but produced no change in the number of mature invadopodia in 
cells expressing cortactin-Y421F (Fig. 6). Therefore the increase in invadopodium maturation due to MenaINV 
expression is dependent upon cortactin phosphorylation at tyrosine 421.
Figure 5. MenaINV expression promotes cortactin phosphorylation and invadopodium maturation.  
(A) Representative images of MDA-MB-231 cells transduced with eGFP, eGFP-Mena, eGFP-MenaINV or 
eGFP-Mena11a using a retrovirus and plated on thin gelatin matrix were starved overnight. Cells were fixed 
and stained for cortactin, phospho-Y421 cortactin, and Tks5. (B) Quantification of cortactin phosphorylation 
expressed as the fold change in pY421-cortactin/cortactin ratio localized to punctate invadopodium precursors, 
defined as punctate co-localization of cortactin and Tks5 from (A) (n > 200 invadopodia and 50 cells for 
each condition; three independent experiments). Error bars indicate ± SEM. Data was analyzed for statistical 
significance by unpaired t-test with Welch’s correction for unequal variance. *p < 0.05; ****p < 0.0001.
www.nature.com/scientificreports/
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PTP1B regulates cortactin phosphorylation at invadopodia and opposes the effect of 
MenaINV. Cortactin is phosphorylated at tyrosine 421 in invadopodia by Arg, a tyrosine kinase that is acti-
vated by a variety of upstream signals, including EGF stimulation and β 1-integrin activation21,22,62,63. However 
the process by which cortactin tyrosine 421 is dephosphorylated at invadopodia, and invadopodium matura-
tion is thereby regulated, has not been studied. During hyperosmolarity-induced stress, cortactin phosphoryl-
ation at tyrosine 421 and 446 has been shown to be regulated by the non-receptor protein tyrosine phosphatase 
PTP1B53. Furthermore, cortactin phosphorylation at tyrosine 421 was upregulated nearly 5-fold in a quantitative 
mass-spectroscopy analysis of phospho-tyrosines in PTP1B deficient mice54. An analysis of a large cohort of 
histological samples from breast cancer patients showed that PTP1B expression is associated with less aggres-
sive, estrogen-receptor-positive disease, and overall greater survival64. Interestingly, pharmacological inhibition 
of PTP1B activity has been shown to produce higher rates of breast carcinoma cell invasion in vitro as well as in 
vivo43. We therefore investigated whether PTP1B expression has an additional role in suppressing tumor invasion 
by regulating the phosphorylation of cortactin Y421 at invadopodia.
We found that PTP1B localizes to more than 50% of invadopodium precursors in both MDA-MB-231 and 
MTLn3 cells (Fig. 7A; Supplementary Fig. S4). PTP1B localized to approximately 80% of invadopodium pre-
cursors in MDA-MB-231 cells expressing eGFP alone, but when eGFP-MenaINV was overexpressed PTP1B 
Figure 6. The increase in invadopodium maturation produced by MenaINV is dependent on cortactin 
phosphorylation. (A) Representative images of MDA-MB-231 cells stably expressing wild-type cortactin 
or cortactin in which tyrosine 421 was mutated to phenylalanine (Y421F), with transient knock down of 
endogenous cortactin using siRNA and transient forced expression of eGFP-MenaINV or an eGFP control vector. 
Cells were plated on Alexa Fluor 405 labeled FN/gelatin and stained for cortactin and Tks5. (B) Quantification 
of mature invadopodia, identified as cortactin- and Tks5-rich puncta co-localizing with a degradation hole, 
for the images shown in (A) (n < 50 cells; three independent experiments). Data was analyzed for statistical 
significance by unpaired t-test with Welch’s correction for unequal variance. **p < 0.01; ***p < 0.001; ns = not 
significant.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:36142 | DOI: 10.1038/srep36142
Figure 7. PTP1B localizes to invadopodium precursors, where it suppresses pY421-cortactin 
phosphorylation and reverses MenaINV-induced cortactin phosphorylation. (A) Representative images of 
MDA-MB-231 cells immuno-stained for cortactin, Tks5 and PTP1B, imaged on a TIRF microscope showing 
PTP1B localizing to invadopodium precursors. (B) Western blot showing MDA-MB-231 lysates treated with 
control or one of two PTP1B-targeting single siRNAs for 48 h and stained for PTP1B using a monoclonal 
antibody (n = three independent experiments). (C) PTP1B KD increases Y421-cortactin phosphorylation. 
Representative images of MDA-MB-231 cells transfected with control or one of two PTP1B siRNAs for 
48 h, plated on 0.2% gelatin matrix and starved overnight. Cells were then fixed and stained for cortactin, 
phospho-Y421 cortactin, and Tks5. (D) Cortactin phosphorylation expressed as the fold change in pY421-
cortactin/cortactin ratio localized to invadopodium precursors, defined as punctate co-localization of 
cortactin and Tks5 (n < 100 invadopodia; three independent experiments). (E) eGFP-PTP1B overexpression in 
MDA-MB-231 cells. Western blot showing lysates from MDA-MB-231 cells stably expressing eGFP or eGFP-
MenaINV were transfected with 0.5 ug of an empty-vector control or pEGFP-PTP1B-HA C3 DNA and stained for 
PTP1B. (n = three independent experiments) (F) eGFP-PTP1B overexpression suppresses basal and MenaINV-
increased Y421-cortactin phosphorylation. Representative images from cells in (E), after fixation and staining for 
pY421-cortactin, cortactin and Tks5. (G) eGFP-PTP1B overexpression suppresses basal and MenaINV-increased 
Y421-cortactin phosphorylation. Quantification of the fold change in pY421-cortactin/cortactin ratio localized 
to invadopodium precursors, defined as punctate co-localization of cortactin and Tks5 (n > 100 invadopodia; 
three independent experiments). Error bars indicate ± SEM. Data was analyzed for statistical significance by 
unpaired t-test with Welch’s correction for unequal variance. *p < 0.05, **p < 0.01; ***p < 0.001; ****p < 0.0001.
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localization to invadopodium precursors dropped from 80% to less than 50% (Fig. 8A,B). When we compared 
invadopodium precursors that contained eGFP-MenaINV with those that did not, we found that significantly 
fewer invadopodia containing MenaINV also contained PTP1B (Fig. 8C), indicating that MenaINV and PTP1B 
localization to invadopodia are inversely correlated. Reduction of PTP1B expression with siRNA, to less than 
20% of control levels (Fig. 7B; Supplementary Fig. S4), increased the level of cortactin phosphorylation at 
tyrosine 421 within invadopodia of both MDA-MB-231 (Fig. 7C,D) and MTLn3 (Supplementary Fig. S4) cells 
to a similar extent as MenaINV overexpression. Knock down of PTP1B expression by siRNA also significantly 
increased the number of mature invadopodia per cell and the level of matrix degradation per invadopodium 
(Supplementary Fig. S4).
We further interrogated the role of PTP1B in regulation of cortactin phosphorylation in invadopodia using 
forced-expression of exogenous PTP1B (eGFP-PTP1B-HA). We found that eGFP-PTP1B-HA expression in both 
MDA-MB-231 and MTLn3 cells decreased cortactin tyrosine 421 phosphorylation at invadopodia relative to cells 
expressing eGFP alone (Fig. 7E–G; Supplementary Fig. S4), and eGFP-PTP1B-HA expression in MTLn3 cells 
significantly reduced the number of mature invadopodia per cell relative to eGFP alone (Supplementary Fig. S4). 
Furthermore, PTP1B forced-expression in cells stably expressing eGFP-MenaINV reversed the increase in tyrosine 
421 cortactin phosphorylation at invadopodia caused by eGFP-MenaINV relative to cells expressing eGFP alone 
(Fig. 7G). Thus, PTP1B regulates cortactin phosphorylation at tyrosine 421 in invadopodium precursors of both 
rat and human breast carcinoma, limiting invadopodium maturation. While MenaINV reduces PTP1B localization 
to invadopodium precursors, decreases cortactin phosphorylation at tyrosine 421, and promotes invadopodium 
maturation.
Figure 8. MenaINV reduces PTP1B localization to invadopodium precursors. (A) Representative images of 
MDA-MB-231 cells expressing eGFP or eGFP-MenaINV and immuno-stained for cortactin, Tks5 and PTP1B, 
imaged on a TIRF microscope. (B) The percentage of invadopodium precursors co-localizing with PTP1B 
staining was quantified from the images shown in (A) (n > 50 cells). (C) Invadopodium precursors from 
MDA-MB-231 cells expressing eGFP-MenaINV in the images shown in (A) were divided into those with (+ )  
or without (− ) MenaINV localization, and the proportion of each population with PTP1B localization was 
quantified (n > 50 cells). Error bars indicate ± SEM. Data was analyzed for statistical significance by unpaired 
t-test with Welch’s correction for unequal variance. ****p < 0.0001.
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Discussion
Our previous work has demonstrated the role of MenaINV as a central regulator of breast carcinoma cell invasion, 
ECM remodeling, intravasation, and metastasis39,40,44,45,48,51. We have also established that MenaINV expression 
is significantly higher in metastatic primary breast tumors58, correlates with disease recurrence and outcome in 
breast cancer patients39 and correlates with TMEM, a prognostic marker for metastasis in ER + /HER2- breast 
cancer patients44,48–50. In this study we further elucidate the relationship between MenaINV and breast carcinoma 
cell invasion and dissemination by focusing on the effect of Mena isoform expression on invadopodium matu-
ration, important because the invadopodium is a protrusive structure essential for intravasation9,15,48. Based on 
the findings presented here, we propose a model in which MenaINV localizes to the invadopodium precursor and 
increases cortactin phosphorylation at tyrosine 421 to promote invadopodium maturation by interfering with 
PTP1B (Fig. 9).
In particular, we found that the effect of MenaINV on increasing invadopodium maturation is specific to the 
INV isoform and that Mena and Mena11a did not show similar effects. It should be noted that previously it was 
reported that exogenous Mena expression increases the level of ECM degradation in MTLn3 cells45, while here 
we have found that exogenous Mena alone does not produce a significant increase in the number of mature inv-
adopodia per cell. Since degradation area is not directly related to the number of mature invadopodia in a cell 
but rather is a measurement also related to the extent of cell motility over the ECM degradation target, we used 
in our study direct measures of mature invadopodium number to avoid misinterpretation of the effects of Mena 
isoform expression on invadopodium maturation. We found that MenaINV localizes to invadopodium precursors 
during the period in which they are stabilized at the plasma membrane20, before peak cortactin phosphorylation 
occurs17. We provide evidence that PTP1B regulates cortactin phosphorylation at tyrosine 421 in invadopodia. 
Our current results showing that MenaINV suppresses the activity of PTP1B toward cortactin within invadopodia 
are consistent with our previous work showing that, in EGF stimulated cells, MenaINV suppresses the activity of 
PTP1B towards cortactin and other substrates43.
The phosphorylation of cortactin tyrosine 421 at invadopodia is necessary for the release of cofilin from cort-
actin, and recruitment of an Nck1/N-WASP/Arp2/3 complex, both of which are essential for actin-polymerization 
at the invadopodium precursor, and necessary to support cofilin-dependent actin polymerization that is required 
for invadopodium maturation into a matrix-degrading structure17,22–25. Our finding that MenaINV is able to 
increase tyrosine 421 cortactin phosphorylation at invadopodia in the absence of exogenously-added soluble 
growth factors, such as EGF, raises the possibility that other cues, such as contact with the ECM can trigger this 
effect in invadopodia. β 1 integrin binds to and activates Arg at invadopodia, leading to enhanced cortactin phos-
phorylation at tyrosine 421, and β 1 integrin activity is necessary for invadopodium maturation61–63. Mena forms 
an adhesion-regulated complex with α 5β 1 integrin, a fibronectin receptor38, and MenaINV enhances the ability 
of cells to migrate up fibronectin gradients present near the vasculature39. In limiting PTP1B’s regulation of cort-
actin phosphorylation at invadopodia, MenaINV may sensitize carcinoma cells to produce mature invadopodia 
in response to a variety of β 1-integrin ligands present in the tumor microenvironment, such as fibronectin and 
type-1 collagen65–67.
Figure 9. Model of MenaINV recruitment to and signaling at invadopodia. MenaINV arrives early during 
invadopodium precursor assembly at approximately the same time as Tks5 arrival. Tks5 begins stabilization 
of the precursor by binding it to sites of PI(3,4)P2 at the plasma membrane20. This is consistent with the 
recruitment of Mena and Tks5 to the plasma membrane at PI(3,4)P2-rich sites by Lamellipodin (Lpd)20,35. 
MenaINV then displaces PTP1B from the invadopodium precursor (red line), preventing PTP1B from 
dephosphorylating cortactin at tyrosine 421 (dotted arrow). Y421-cortactin (red) phosphorylation leads to 
cofilin release and actin severing to produce a greater concentration of barbed ends. Cortactin phosphorylation 
also recruits Nck1 to the invadopodium, which acts through N-WASP to produce greater levels of Arp2/3-
mediated actin branching from newly elongating barbed ends produced by cofilin severing25. Mena promotes 
actin polymerization by displacing Capping Protein (CP) from the barbed end, and MenaINV promotes 
additional actin polymerization at invadopodia through enhanced cortactin phosphorylation at tyrosine 421, as 
described above, which leads to invadopodium elongation and maturation.
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By upregulating MenaINV expression, tumor cells may become more versatile in their ability to produce stable, 
mature invadopodia in a variety of microenvironments, including those where insoluble ligands are predom-
inantly present to stimulate invadopodium maturation such as at the basement membranes of blood vessels. 
Fibronectin in particular has been shown to be abundant in the tumor stroma and fibronectin expression has 
been shown to correlate positively with tumor aggressiveness and decreased survival68–71. Even before tumor 
cells are exposed to soluble chemoattractants released from the vasculature, MenaINV expression would allow the 
cells to invade through the fibronectin-rich basement membrane and surrounding stroma by producing more 
stable invadopodium protrusions. MenaINV-induced increases in haptotaxis and matrix degradation in response 
to insoluble ligands provide additional mechanisms by which metastatic cancer cells may resist EGFR inhibitor 
treatment72.
Mena isoforms show similar localization to invadopodia, but have different effects on invado-
podium signaling. The INV exon is located just downstream of Mena’s EVH1 domain. The EVH1 domain is 
responsible for Mena localization to the leading edge, focal adhesions and filopodia via binding to proteins con-
taining a consensus sequence (F/WPXøP, X = any residue, ø = hydrophobic residue)30,33,37. Here we have found 
that eGFP-tagged Mena, MenaINV, Mena11a, and endogenous Mena isoforms, localize to a similar proportion of 
invadopodium precursors. Exogenous Mena, MenaINV and Mena11a arrive at invadopodium precursors within 
seconds of each other, but MenaINV was able to increase invadopodium maturation to a much greater extent than 
either of the other isoforms. Though Mena11a arrives at invadopodium precursors an average of ~14s later than 
MenaINV, all three isoforms arrived well before the minimum two-minute lag-time between precursor formation 
and matrix degradation. Furthermore, the slightly later arrival of Mena11a at invadopodium precursors does 
not explain its inability to promote cortactin phosphorylation at invadopodia in steady-state conditions, unlike 
MenaINV expression (Fig. 5; Supplementary Fig. S3). These results suggest that the INV exon does not significantly 
alter Mena localization to invadopodia, but rather affects Mena function at invadopodia. PTP1B also contains a 
domain (LEPPPEHIPPPP) resembling the consensus EVH1 binding motif, and has been shown to bind to Mena 
containing an intact EVH1 domain43. MenaINV expression has been shown to prevent PTP1B association with 
the EGFR43, and here we show that MenaINV decreases association of PTP1B with invadopodia (Fig. 8). Hence, 
our data are consistent with the speculation that the INV exon enables Mena to disrupt the association of PTP1B 
with its substrates and this has the consequence of increasing invadopodium maturation by interfering with the 
proximity of PTP1B to cortactin at the invadopodium, thereby suppressing cortactin tyrosine dephosphorylation 
at that site.
Interestingly, we found that eGFP-Mena expression also increases invadopodium maturation in MDA-MB-231 
cells (Fig. 2A,B), which endogenously express detectible MenaINV in vitro60. However, eGFP-Mena expression did 
not produce a significant increase in invadopodium maturation in MTLn3 cells (Fig. 2C,D), which do not express 
detectible MenaINV 44. Ena/VASP proteins, including Mena, have been shown to form hetero- and homotetram-
ers via their EVH2 domains42,73,74. Since co-expressed Mena isoforms can associate in heterotetramers a given 
Mena isoform may thereby influence the localization and stability of other Mena isoforms that are co-expressed. 
Such heterotetramers may therefore allow exogenous Mena to recruit and/or stabilize endogenous MenaINV at 
invadopodia in MDA-MB-231 cells. Thus, Mena expression may promote invadopodium maturation through its 
association with MenaINV in tetramers, yet this would not be expected to occur in cell lines that do not express 
MenaINV endogenously.
Another possible reason why Mena overexpression can promote invadopodium maturation is through its 
effects on actin polymerization45. It seems plausible that MenaINV has a specific role in displacing PTP1B while 
increased levels of Mena (and/or MenaINV) would enhance actin polymerization. However, this seems less likely 
since the switch to invadopodium maturation precedes cofilin-dependent actin polymerization (Fig. 9) suggest-
ing that the effect provided by endogenous MenaINV on cortactin phosphorylation is the dominant factor in 
invadopodium maturation. Additional studies into the effects of co-expression and interaction of these Mena 
isoforms may yield valuable insights into their respective functions in tumor cells.
Though the Mena isoforms assessed in this study co-localized with the invadopodium markers Tks5 and cort-
actin, we found that the Mena isoform distributions at invadopodia were more diffuse than either of the two core 
markers Tks5 and cortactin. Mena isoforms have been shown to bind and be recruited by PH domain-containing 
proteins such as Lamellipodin33,35, and by SHIP275 which in turn bind to phosphoinositides at the plasma mem-
brane. The localization of the phosphoinositide PI(3,4)P2 to invadopodia has recently been characterized20, 
and localizes to invadopodia with the similarly diffuse distribution that we observe here for Mena isoforms 
(Fig. 1A–C; Supplementary Fig. S1). Mena is also known to bind the barbed end of actin filaments via its EVH2 
domain73, and the localization of Mena to specific subcompartments of invadopodia defined by actin, phospho-
inositides and adhesion proteins remains unclear. Answering this question will require higher-resolution imaging 
of the association of Mena isoforms with these invadopodum subcompartments, and may shed key insights into 
how Mena isoforms are recruited to and regulate invadopodia.
PTP1B as a regulator of cortactin phosphorylation and invadopodium maturation. One of the 
key findings of our study is the identification of the phosphatase PTP1B as a regulator of cortactin phosphoryla-
tion at invadopodia in both rat and human breast carcinoma cells. This finding has implications concerning the 
consideration of PTP1B as a therapeutic drug target, and supports evidence that PTP1B expression is a potential 
prognostic marker in breast carcinoma patients64. Interest in the role of PTP1B in breast cancer progression began 
with the finding that PTP1B is overexpressed in human breast carcinoma cells transformed with the neu onco-
gene76 and overexpressed in the majority of breast tumors in patients relative to normal breast tissue77. However 
more recent analysis of tumors from larger cohorts of breast cancer patients indicates that PTP1B expression is 
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associated with less aggressive, estrogen-receptor-positive disease, and overall greater survival64. In addition, a 
variety of substrates have been found for PTP1B that support its role as a tumor suppressor52.
Much of the evidence for PTP1B as a tumor promotor has come from its association with ErbB2-positive 
tumorigenesis78, though PTP1B’s role in later stages of tumor progression has received relatively little attention. 
Evidence for a pro-metastatic role for PTP1B has centered on PTP1B’s ability to promote Src kinase activity79,80, 
and PTP1B has previously been reported to promote, rather than suppress, invadopodium formation in breast 
cancer cells after being released from the ER membrane by calpain cleavage81,82. Cortesio et al.81 found that 
PTP1B dephosphorylation of Src kinase at tyrosine 529 increased Src activity, thereby promoting invadopodium 
formation. However, the increase in Src phosphorylation measured was at the whole cell level rather than specif-
ically at invadopodia. Furthermore Cortesio et al.81, observed an increase in invadopodia (identified by cortactin 
and actin co-localization) but did not address the possibility that PTP1B may have distinct effects on invadopo-
dium precursor initiation and the maturation of precursors to matrix-degrading structures as indicated in Fig. 9. 
Since cortactin has been found to co-localize with actin in endosomes, which appear as cortactin- and actin-rich 
cytoplasmic puncta83, actin-cortactin co-localization is not specific to the invadopodium core and not definitive 
to identify invadopodia. The cortactin and Tks5 markers used to identify the invadopodium core in our study 
co-localize only at invadopodia, and have highly divergent localization patterns outside of invadopodia. When we 
used cortactin and Tks5 as invadopodium markers in breast tumor cells, we found that knocking down PTP1B 
with siRNA increased invadopodium-associated ECM degradation and the number of mature invadopodia per 
cell (Supplementary Fig. S4). Furthermore, expression of exogenous PTP1B decreased the number of mature 
invadopodia per cell (Supplementary Fig. S4), indicating that PTP1B suppresses invadopodium maturation.
The discovery of MenaINV-dependent invadopodium maturation provides important new insight into the 
pro-metastatic effects of this isoform. Our results indicate that the effects of MenaINV on tumor cell phenotype, 
including the sensitization of receptor tyrosine kinases (RTKs)43, invadopodium maturation, migration51 and 
dissemination48, result in part from the ability of MenaINV to limit PTP1B-dependent dephosphorylation of RTKs 
and cortactin in tumor cells resulting in MenaINV-dependent invadopodium maturation which is required for 
tumor cell intravasation9,10,15. Furthermore, the discovery of MenaINV-dependent invadopodium maturation is 
consistent with the functional relationship between Mena isoform expression patterns and TMEM intravasation 
sites found in breast tumors29,48,84, two prognostics which are independently predictive of metastatic recurrence 
and mortality in breast cancer patients29,46,47,49,50.
Methods
Cell Lines and Cell Culture. MDA-MB-231 cells were cultured in DMEM (Life Technologies), supple-
mented with 10% FBS (Atlanta Biologicals, Flowery Branch, GA) and 0.5% penicillin/streptomycin, and MTLn3 
cells were cultured in α -MEM supplemented with 5% FBS (Gemini Bio-Products, West Sacramento, CA) and 
0.5% penicillin/streptomycin. In experiments involving serum starvation, MDA-MB-231 were starved overnight 
in DMEM containing 0.5% FBS and 0.8% BSA before adding L15 media supplemented with 0.345% BSA for an 
additional 3 h prior to fixation. MTLn3 cells were starved for 3–4 h in L15 media supplemented with 0.345% 
BSA prior to fixation, or stimulation with 5 nM mouse EGF (Life Technologies) during time-lapse imaging, as 
described previously20. EGF stimulation used during time-lapse imaging was performed in a homeostasis cham-
ber maintained at 37 °C. MTLn3 and MDA-MB-231 cells stably expressing eGFP, eGFP-Mena, eGFP-MenaINV 
or eGFP-Mena11a were created using retroviral vectors, with retroviral packaging, infection, and fluorescence 
activated cell sorting performed as described elsewhere85. MDA-MB-231 cells expressing murine cortactin and 
mutant cortactin-Y421F were generated using single-site directed mutagenesis of cortactin by PCR, cloning the 
mutated or wild-type construct into N1-TagRFP (Clontech Laboratories), and sub-cloning this into the retroviral 
expression vector pLSXN as described previously22.
Fine Needle Aspiration of MTLn3 Xenografts. FNA was performed as described previously44 from 
SCID mice 3 weeks after injection of MTLn3 cells into the mammary gland. In brief, carcinoma cells were col-
lected with a 25-gauge needle, centrifuged at low speed, resuspended in α -MEM containing 15% FBS, plated on 
0.2% unlabeled gelatin for 3–4 h, washed 3 times in warm PBS to remove extracellular debris, and fixed in 3.7% 
paraformaldehyde. All procedures were conducted in accordance with the NIH regulations and approved by the 
Albert Einstein College of Medicine animal use committee.
Antibodies, Drugs and DNA Constructs. The cortactin (ab33333), PTP1B EP1837Y (ab52650) and 
PTP1B EP1841Y (ab75856) antibodies were obtained from Abcam (Cambridge, MA). The Tks5 (sc30122) 
antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and labeled with Alexa Fluor 568 dye 
(Molecular Probes, Eugene, OR) for pY421-cortactin staining experiments as per the manufacturer’s instruc-
tions. The phospho-Y421 cortactin (C0739) antibody was from Sigma-Aldrich (St. Louis, MO). The PTP1B 
inhibitor (539741) was from Calbiochem (San Diego, CA). All secondary antibodies were Alexa Fluor conju-
gated and obtained from Molecular Probes (Life Technologies, Carlsbad, CA). The Pan-Mena antibody was pur-
chased from Novus Biologicals (Littleton, CO; Cat# NBP1–87914). The antibody specific for MenaINV used in 
this study has been described elsewhere59. pEGFP-PTP1B C3 was a gift from Anna Huttenlocher (University 
of Wisconsin, Madison, WI). pCAX-eGFP and pCAX-eGFP-MenaINV vectors were produced by the Gertler lab 
(MIT, Cambridge, MA)45.
Production of Mena11a antibody. Rabbit polyclonal antibodies were generated by Covance. Animals 
were immunized with a peptide containing the sequence of the 11a exon of Mena11a.
Consistent with the specificity of this antibody, a western blot of MTLn3 cells containing eGFP-Mena11a con-
tain a single band for endogenous Mena11a when stained with the anti-Mena11a IgG, corresponding in size with 
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the band seen when the same blot was stained for all Mena isoforms (Pan-Mena), and a more intensely-staining 
band corresponding to eGFP-Mena11a (Fig. 3G) as has been described previously44. Western blots of lysates from 
cells previously characterized as containing Mena11a (MCF7)86 and parental MTLn3 cells also contained a band 
corresponding in size with endogenous Mena11a (Supplementary Fig. S2E). Additionally, western blots of cells 
obtained from mammary tumors in wild-type or Mena-null (Mena−/−) PyMT mice demonstrate the specificity 
of this antibody. Lysates obtained from WT PyMT tumor cells contain a band corresponding to endogenous 
Mena11a when stained with the anti-Mena11a IgG while lysates from Mena-null PyMT tumor cells do not con-
tain a corresponding band (Supplementary Fig. S2E). All procedures were conducted in accordance with the NIH 
regulations and approved by the Albert Einstein College of Medicine animal use committee.
RNA interference and transfection. Non-targeting siRNA (D-001210-01), siRNAs targeting human PTP1B 
(J-003529-15, 5′ -CUACCUGGCUGUGAUCGAA-3′ ; J-003529-14, 5′ -GGAGAAAGGUUCGUUAAAA-3′ ), 
siRNA targeting rat PTP1B (J-080071-10, 5′ -GAUCGAGGGUGCAAAGUUC-3′ ) and siGENOME siRNA 
Smart Pool targeting human cortactin (M010508-00-0005) were obtained from Dharmacon (GE). MenaINV- and 
Mena11a-targeting siRNAs were purchased from Ambion (Custom Select siRNA). Transfection of siRNA and 
DNA into MDA-MB-231 cells was performed using the Lonza Nucleofector V kit, suspending 2 μ M of siRNA or 
1 μ g of DNA in the included Lonza solution and electroporating 1 × 106 cells using the Amaxa Nucleofector II 
device 24 h prior to the experiment for DNA constructs, and 72 h prior to the experiment for siRNA. Transfection 
of siRNA into MTLn3 cells was performed with Oligofectamine reagent (Life Technologies) 48 h prior the exper-
iment, with an RNA concentration of 200 nM, except pan-Mena siRNA was used at 20 nM. DNA constructs were 
transfected at 1 ug/mL using Lipofectamine reagent (Life Technologies) as described previously17 24 h prior to 
the experiment.
Invadopodium staining and matrix degradation assay. A 0.2% gelatin (Sigma-Aldrich) solution was 
labeled with Alexa Fluor 405 dye (Molecular Probes, Eugene, OR) and MatTek dishes (MatTek Corporation, 
Ashland, MA) were coated with this conjugated gelatin as described elsewhere87. Briefly dishes were treated 
in 1N HCL before coating them with 50 μ g/mL Poly-L-lysine (Sigma-Aldrich) and the Alexa 405 conjugated 
0.2% gelatin diluted 1:40 in unlabeled 0.2% gelatin. This matrix was then crosslinked with a 0.1% glutaraldehyde 
solution, and the crosslinking quenched with 5 mg/ml sodium borohydride. Immediately prior to cell plating, 
MatTek dishes were pre-treated with media containing serum for 30 minutes, which we have found sufficient 
to add detectible levels of fibronectin. In cortactin phospho-mutant experiments, the invadopodium assay was 
performed on glutaraldehyde cross-linked, 0.2% gelatin coated dishes as described above, layered with Alexa 
Fluor 405-labeled fibronectin. 2 × 105 MDA-MB-231 cells were plated on the Alexa Fluor 405-labeled matrices 
for 4 h, or 1 × 105 MTLn3 cells for 12 h, at steady state prior to fixation in 4% PFA. Cells were permeabilized in 
0.1% Triton X-100, blocked in a 2% BSA and 2% FBS solution in PBS, and primary and secondary antibod-
ies were diluted in this same blocking solution. In experiments involving MDA-MB-231 cells stably expressing 
TagRFP-Cortactin-WT and –Cortactin-421F, endogenous human cortactin was knocked down 72 h prior to 
the start of the experiment and confirmed by immunoblot. As described elsewhere62, invadopodium precur-
sors were defined as cortactin- and Tks5-rich puncta not co-localizing with a degradation hole in the Alexa 
Fluor 405-labeled gelatin, while those double-staining puncta that did co-localize with degradation holes were 
defined as mature invadopodia. For this assay, images of the fixed cells in PBS were taken on a DeltaVision Core 
Microscope (Life Sciences, GE) using a CoolSNAP HQ2 camera (Photometrics, Tuscon, AZ), a 60x oil objective 
with 1.4 numerical aperture (NA), a standard four-channel filter set and softWoRx software.
Time lapse imaging of live cells for arrival kinetics. MTLn3 cells expressing eGFP-Mena, 
eGFP-MenaINV or eGFP-Mena11a were transfected for 24 h with TagRFP-cortactin. 1 × 105 cells were then plated 
on unlabeled gelatin overnight in complete media, serum-starved for 3-4 h in L15 media, and stimulated with 
5 nM EGF to induce invadopodium precursor formation during imaging. The cells were imaged with frames 
taken every three seconds on a custom-built total internal reflection fluorescence (TIRF) microscope, used to 
minimize background, and the CRISP autofocus system (ASI, Eugene, OR) to stabilize the focus while images 
were collected using an Andor iXONEM+ EMCCD camera (Oxford Instruments), a 60x oil objective lens with 1.45 
NA and a 2488-561-633rpc multi-bandpass mirror to enable multi-channel imaging.
Phospho-cortactin assay and quantitative Immunofluorescence. 3 × 105 MDA-MB-231 cells were 
plated on unlabeled 0.2% gelatin matrix for 4 h prior to starvation in DMEM. Human EGF in L15 media at con-
centrations of 0.25 nM and 2.5 nM, or the L15-only control, was added for 3 minutes in a 37 °C water bath, and 
the cells were fixed in 4% PFA. PTP1B inhibition was accomplished by incubating cells in 10 μ M PTP1B inhibitor 
dissolved in DMSO or an equal volume of DMSO alone, and diluted in L15 media, for 1 h prior to EGF treatment. 
PTP1B or control siRNA was transfected into cells at a concentration of 2 μ M 48 h prior to EGF stimulation. 
pEGFP-PTP1B-HA C3 or pEGFP C3 plasmids were transfected into cells 24 h prior to EGF stimulation.
The intensity of cortactin and tyrosine 421 cortactin phosphorylation staining was quantified and expressed 
as the relative fold change in pY421-cortactin/cortactin ratio. Images for the invadopodium assay and tyrosine 
421 cortactin phosphorylation staining were acquired on the DeltaVision Core Microscope (Applied Precision) 
with a CoolSNAP HQ2 camera, a 60x NA 1.4 oil objective, standard 4-channel filter set, and softWoRx image 
acquisition software.
Statistical Analysis. Statistical analysis was performed with one-way analysis of variance (one way-ANOVA) 
analysis and Tukey’s multiple comparisons test or unpaired t-tests with Welch’s correction for unequal variance, using 
GraphPad Prism software. All bar graphs depict mean ± SEM, scatter plots depict 95% confidence intervals (CI).
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